Ambit raises $15M; Takeda files TAK-491 app with EMA;

 @FierceBiotech: Why are women thriving in the top ranks of biotech? Article | Follow @FierceBiotech

Special Report: Pharma's Biggest Flops. Report

Special Report: Pharma manufacturing consent decrees: 16 black holes. Report

Xconomy reports that Ambit Biosciences has raised $15 million to help fund its work on new small molecule cancer drugs. The funds were disclosed in a recent regulatory filing. Story

> Takeda Global Research & Development Centre submitted an application for azilsartan medoxomil (TAK-491), an angiotensin II receptor blocker, to the EMA for the treatment of essential hypertension. Takeda release

> Seoul, Korea-based BioMolecular Therapeutics has launched. The RNAi therapeutics company says it has a proprietary technology designed to reduce significantly deleterious side effects triggered by conventional siRNA. BioMolecular release

> Lung cancer has always been tough to detect at an early stage, proving an elusive foe for a number of proposed screening tests. But a group of cancer experts at the M.D. Anderson Cancer Center say that a protein that binds to DNA could prove to be the biomarker needed to make early detection--and swift treatment--into a reality. Article

> Chinese researchers probe for biomarkers to guide Tarceva use. Report

> Salix Pharmaceuticals has agreed to pay up to roughly $130 million for the licensing rights to a new imaging technology that can be used to spot precancerous lesions in the colon. Article

And Finally... Scientists say that our brains have the ability to determine the shape of an object simply by processing specially-coded sounds, without any visual or tactile input. Release

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.